The molecular mechanisms involved in sensitivity to PI3K inhibitors are yet to be clarified in order to translate preclinical activity into clinical benefit, and to date the development of PI3K inhibitors in advanced GC is still in the preclinical stage [129]. This evidence concerns the gene PIK3CA and gastric cancer.